The Japanese patent granted to Galena’s GALE-401 drug allows it exclusivity until the year 2029, though this comes without possibility for patent extensions. The company is expected to benefit from the available monopoly over the long period.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.